AI is in Every Pharma Strategy Deck
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
From Snapshots to Movies
Elevating Drug Safety
Clinically Validated Probiotics
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
GE Healthcare
President & CEO
Our current business focus and strengths are in the areas of bioprocessing proteins cellular analysis cell handling and tools for cell therapy Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide
We are particularly excited about the sample collection and storage opportunity with the FTA product lineWe have a stron...
Articles
Syringe-like Bacterial Nanomachine Emerges as Potential Therapeutics Delivery Device
CIS are syringelike cellpuncturing machines Bacteria deploy it for various natural functions including cellcell communications defence and in endosymbionts to interact with the hosts CIS translocate effectors molecules
Research Insights
Model Based on COVID-19 Evidence to Predict and Improve Pandemic Control
The COVID pandemic has dramatically affected all of humanity but it also provided an enormous amount of data which may provide valuable lessons on how to effectively face future events of similar characteristics
Case Studies
<sup>14</sup>C microtracer+Accelerator Mass Spectrometry - Xceleron Case Studies
Introduction Xceleron is a world leader in the use of Accelerator Mass Spectrometry AMS analytical technology in pharmaceutical food technology crop protection and biobased product applications Our primary business is in pharmaceutical research and development Since we have been helping to design preclinical and clinical investigations around the
Techno Trends
Asia's Regulatory Frameworks Evolve to Enhance Drug Development Efficiency
New regulatory frameworks aim to streamline drug development processes across Asia
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Data-Enriched Edible Pharmaceuticals (DEEP) as Patient-Tailored Drug Products
Natalja Genina, Associate professor at University of Copenhagen (UCPH), Denmark. Her research interest include fabrication of advanced drug delivery systems and their integration into digital health. Dr. Genina has a remarkable publication record in her research field.
Professor, UCPH
Associate Professor, UCPH
Sofia Kälvemark Sporrong, Professor at Uppsala University, Sweden. Expert in social pharmacy. Kälvemark Sporrong is a social scientist doing research within the area of pharmaceuticals. Her research interests include the patient perspective on drug use, pharmaceutical policy and professional ethics for health care staff.
Automation in Pharmaceutical Sector by Implementation of Artificial Intelligence
Amol Shinde is Assistant Manager in Department of Medical Affairs and Pharmacovigilance at Unichem Laboratories Ltd., India with approx. 7 years of working experience in various corporate of pharma industries. He has published 4 papers in international and national journals.
Use of Steroids in COVID-19 patients
Anoop Kumar currently working as Assistant Professor in Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India. He has authored more than 70 research and review articles and 10 book chapters in International Journal of repute. His research interests are Drug repurposing, Meta-analysis, Risk and benefit analysis of drugs and Pharmacoeconomic studies.
M&A, Partnerships & Ecosystem Models in Biopharma
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
Emerging Technologies in Pharmaceutical Sciences
Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.
press releasesRead more...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
LATEST NEWSRead more...
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
